The dampening of T-cell response observed with long term cediranib treatment that facilitated anti–PD-1 combination in 60577 model, was a similar mechanism that dictated successful combination of PARP inhibitors with anti–PD-1 therapy in ovarian cancer patients (35). The gene discussed is PDCD1; the disease is ovarian carcinoma.